Your browser doesn't support javascript.
loading
Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.
Dekker, I; Leurs, C E; Hagens, M H J; van Kempen, Z L E; Kleerekooper, I; Lissenberg-Witte, B I; Barkhof, F; Uitdehaag, B M J; Balk, L J; Wattjes, M P; Killestein, J.
Afiliación
  • Dekker I; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology & Nuclear Medicine, MS Center Amsterdam, Amsterdam Neuroscience, De Boelelaan 1117 Amsterdam, the Netherlands; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, D
  • Leurs CE; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, De Boelelaan 1117 Amsterdam, the Netherlands.
  • Hagens MHJ; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, De Boelelaan 1117 Amsterdam, the Netherlands.
  • van Kempen ZLE; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, De Boelelaan 1117 Amsterdam, the Netherlands.
  • Kleerekooper I; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, De Boelelaan 1117 Amsterdam, the Netherlands.
  • Lissenberg-Witte BI; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, De Boelelaan 1117 Amsterdam, the Netherlands.
  • Barkhof F; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology & Nuclear Medicine, MS Center Amsterdam, Amsterdam Neuroscience, De Boelelaan 1117 Amsterdam, the Netherlands; Institutes of Neurology and Healthcare Engineering, UCL, London, United Kingdom.
  • Uitdehaag BMJ; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, De Boelelaan 1117 Amsterdam, the Netherlands.
  • Balk LJ; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, De Boelelaan 1117 Amsterdam, the Netherlands.
  • Wattjes MP; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology & Nuclear Medicine, MS Center Amsterdam, Amsterdam Neuroscience, De Boelelaan 1117 Amsterdam, the Netherlands; Department of Diagnostic and Interventional Neuroradiology, Hannover Medical School, Hannover, Germany.
  • Killestein J; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, De Boelelaan 1117 Amsterdam, the Netherlands.
Mult Scler Relat Disord ; 33: 82-87, 2019 Aug.
Article en En | MEDLINE | ID: mdl-31174043
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Natalizumab / Factores Inmunológicos Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Mult Scler Relat Disord Año: 2019 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Natalizumab / Factores Inmunológicos Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Mult Scler Relat Disord Año: 2019 Tipo del documento: Article Pais de publicación: Países Bajos